Improved targetry and production of iodine-124 for PET studies

Glaser, Matthias; Mackay, D.; Ranicar, A.; Waters, S.L.; Brady, F.; Luthra, Sajinder K.

doi:10.1524/ract.92.12.951.55103

Cited by 23 publications

(25 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Today, for clinical scale production of 124 I, the 124 Te(p,n) 124 I reaction is universally applied, and batch yields of a few gigabecquerels are obtained. The procedure commonly involves irradiation of a 124 TeO 2 target and removal of radioiodine by a distillation process at 755°C . Radioiodine is collected almost quantitatively in 0.3 mL of 0.02M NaOH solution.…”

Section: Novel Positron Emission Tomography Radionuclidesmentioning

confidence: 99%

“…A detailed discussion on the use of different chargedparticle-induced reactions over several energy ranges for the production of novel positron emitters is given in several references. 6,17,18 We consider below 4 radionuclides, namely, 64 Cu, 86 Y, 124 I, and 73 Se. They were mainly developed in our Institute, and the methodologies described here should serve as typical examples of the techniques and technologies involved in the utilization of chargedparticle beams of various energies.…”

Section: Novel Positron Emission Tomography Radionuclidesmentioning

confidence: 99%

“…51 Several nuclear reactions have been investigated for the formation of 86 Y, but the studies have not been exhaustive. A critical evaluation of data for some of the important reactions was performed by Zaneb et al 52 The recommended method for the production of 86 Y is the originally proposed 86 Sr(p,n) 86 Y reaction 48 on a highly enriched target covering the energy range E p = 14 → 7 MeV. The cross section data show considerable spread, but the production methodology is established.…”

Section: Cu (T ½ = 127 H)mentioning

confidence: 99%

See 2 more Smart Citations

Development of novel radionuclides for medical applications

Qaim

Spahn

2017

Labelled Comp Radiopharmac

View full text Add to dashboard Cite

Medical radionuclide production technology is well established. There is, however, a constant need for further development of radionuclides. The present efforts are mainly devoted to nonstandard positron emitters (eg, Cu, Y, I, and Se) and novel therapeutic radionuclides emitting low-range β particles (eg, Cu and Re), conversion or Auger electrons (eg, Sn and Br), and α particles (eg, Ac). A brief account of various aspects of development work (ie, nuclear data, targetry, chemical processing, and quality control) is given. For each radionuclide under consideration, the status of technology for clinical scale production is discussed. The increasing need of intermediate-energy multiple-particle accelerating cyclotrons is pointed out.

show abstract

Section: Novel Positron Emission Tomography Radionuclidesmentioning

confidence: 99%

Section: Novel Positron Emission Tomography Radionuclidesmentioning

confidence: 99%

Section: Cu (T ½ = 127 H)mentioning

confidence: 99%

See 1 more Smart Citation

Development of novel radionuclides for medical applications

Qaim

Spahn

2017

Labelled Comp Radiopharmac

View full text Add to dashboard Cite

show abstract

“…Today almost all the laboratories use this method [cf . [55][56][57][58]. It involves irradiation of a 124 TeO 2 target and removal of radioiodine by a dry distillation process [cf .…”

Section: Production Using Low-energy Reactionsmentioning

confidence: 99%

Development of novel positron emitters for medical applications: nuclear and radiochemical aspects

Qaim¹

2011

Ract

View full text Add to dashboard Cite

In molecular imaging, the importance of novel longer lived positron emitters, also termed as non-standard or innovative PET radionuclides, has been constantly increasing, especially because they allow studies on slow metabolic processes and in some cases furnish the possibility of quantification of radiation dose in internal radiotherapy. Considerable efforts have been invested worldwide and about 25 positron emitters have been developed. Those efforts relate to interdisciplinary studies dealing with basic nuclear data, high current charged particle irradiation, efficient radiochemical separation and quality control of the desired radionuclide, and recovery of the enriched target material for reuse. In this review all those aspects are briefly discussed, with particular reference to three radionuclides, namely 64 Cu, 124 I and 86 Y, which are presently in great demand. For each radionuclide several nuclear routes were investigated but the ( p, n) reaction on an enriched target isotope was found to be the best for use at a small-sized cyclotron. Some other positron emitting radionuclides, such as 55 Co, 76 Br, 89 Zr, 82m Rb, 94m Tc, 120 I, etc., were also produced via the low-energy ( p, n), ( p, α) or (d, n) reaction. On the other hand, the production of radionuclides 52 Fe, 73 Se, 83 Sr, etc. using intermediate energy ( p, xn) or (d, xn) reactions needs special consideration, the nuclear data and chemical processing methods being of key importance. In a few special cases, a high intensity 3 He-or α-particle beam could be an added advantage. The production of some potentially interesting positron emitters via generator systems, for example 44 Ti/ 44 Sc, 72 Se/ 72 As and 140 Nd/ 140 Pr is considered. The significance of new generation high power accelerators is briefly discussed.

show abstract

“…A dry distillation apparatus of 124 I, which was similar to the one used in a previous study (21), was slightly modified. The radioiodine activity in the NaOH trap (0.5 mL; 0.1 M) was monitored by a NaI scintillation detector.…”

Section: Preparation Of Na 124 Imentioning

confidence: 99%

Delivery of Na/I Symporter Gene into Skeletal Muscle Using Nanobubbles and Ultrasound: Visualization of Gene Expression by PET

Watanabe¹,

Horie²,

Funaki³

et al. 2010

J Nucl Med

View full text Add to dashboard Cite

The development of nonviral gene delivery systems is essential in gene therapy, and the use of a minimally invasive imaging methodology can provide important clinical endpoints. In the current study, we present a new methodology for gene therapy-a delivery system using nanobubbles and ultrasound as a nonviral gene delivery method. We assessed whether the gene transfer allowed by this methodology was detectable by PET and bioluminescence imaging. Methods: Two kinds of reported vectors (luciferase and human Na/I symporter [hNIS]) were transfected or cotransfected into the skeletal muscles of normal mice (BALB/c) using the ultrasound-nanobubbles method. The kinetics of luciferase gene expression were analyzed in vivo using bioluminescence imaging. At the peak of gene transfer, PET of hNIS expression was performed using our recently developed PET scanner, after 124 I injection. The imaging data were confirmed using reverse-transcriptase polymerase chain reaction amplification, biodistribution, and a blocking study. The imaging potential of the 2 methodologies was evaluated in 2 mouse models of human pathology (McH/lpr-RA1 mice showing vascular disease and C57BL/10-mdx Jic mice showing muscular dystrophy). Results: Peak luciferase gene activity was observed in the skeletal muscle 4 d after transfection. On day 2 after hNIS and luciferase cotransfection, the expression of these genes was confirmed by reverse-transcriptase polymerase chain reaction on a muscle biopsy. PET of the hNIS gene, biodistribution, the blocking study, and autoradiography were performed on day 4 after transfection, and it was indicated that hNIS expression was restricted to the site of plasmid administration (skeletal muscle). Similar localized PET and 124 I accumulation were successfully obtained in the diseasemodel mice. Conclusion: The hNIS gene was delivered into the skeletal muscle of healthy and disease-model mice by the ultrasound-nanobubbles method, and gene expression was successfully visualized with PET. The combination of ultrasound-nanobubble gene transfer and PET may be applied to gene therapy clinical protocols.

show abstract

Improved targetry and production of iodine-124 for PET studies

Cited by 23 publications

References 21 publications

Development of novel radionuclides for medical applications

Development of novel radionuclides for medical applications

Development of novel positron emitters for medical applications: nuclear and radiochemical aspects

Delivery of Na/I Symporter Gene into Skeletal Muscle Using Nanobubbles and Ultrasound: Visualization of Gene Expression by PET

Contact Info

Product

Resources

About